{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:54Z","timestamp":1794925554037,"version":"4.9.1"},"reference-count":23,"publisher":"BMJ","issue":"6","funder":[{"name":"Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Early fast-acting treatment (EFT) is the aggressive use of fast-acting therapies such as plasmapheresis, intravenous immunoglobulin and\/or intravenous high-dose methylprednisolone (IVMP) from the early phases of treatment. EFT is reportedly beneficial for early achievement of minimal manifestations (MM) or better status with \u22645\u2009mg\/day prednisolone (MM5mg), a practical therapeutic target for myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The current study aimed to clarify which specific EFT regimen is efficacious and the patient characteristics that confer sensitivity to EFT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited a total of 1710 consecutive patients with MG who enrolled in the Japan MG Registry for this large-cohort study. Among them, 1066 with generalised MG who had received immunotherapy were analysed. Prognostic background factors were matched in a 1:1 ratio using propensity score matching analysis between patients treated with EFT (n=350) and those treated without EFT (n=350). The clinical course and time to first achieve MM5mg after starting immunotherapy was analysed in relation to treatment combinations and patient characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Kaplan-Meier analyses showed that EFT had a significant effect on the achievement of MM5mg (p&lt;0.0001, log-rank test; HR 1.82, p&lt;0.0001). Notably, EFT was efficacious for any type of MG, and the inclusion of IVMP resulted in earlier and more frequent achievement of MM5mg (p=0.0352, log-rank test; HR 1.46, p=0.0380). In addition, early administration of calcineurin inhibitors also promoted MM5mg achievement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early cycles of intervention with EFT and early use of calcineurin inhibitors provides long-term benefits in terms of achieving therapeutic targets for generalised MG, regardless of clinical subtype.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2022-330519","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T18:20:40Z","timestamp":1674584440000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9252-1863","authenticated-orcid":false,"given":"Akiyuki","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6726-6781","authenticated-orcid":false,"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-8578","authenticated-orcid":false,"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori P","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Samukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"2024102902000841000_94.6.467.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"2024102902000841000_94.6.467.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2024102902000841000_94.6.467.3","unstructured":"Suzuki S , Masuda M , Uzawa A , et al . n.d. Japan MG registry: chronological surveys over 10 years [in press]. Clin Exp Neuroimmunol."},{"key":"2024102902000841000_94.6.467.4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"2024102902000841000_94.6.467.5","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107"},{"key":"2024102902000841000_94.6.467.6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"2024102902000841000_94.6.467.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"2024102902000841000_94.6.467.8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"2024102902000841000_94.6.467.9","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1007\/s00415-021-10520-x","article-title":"Long-term outcomes and prognostic factors in generalized myasthenia gravis","volume":"268","author":"Ozawa","year":"2021","journal-title":"J Neurol"},{"key":"2024102902000841000_94.6.467.10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J Neurol Sci"},{"key":"2024102902000841000_94.6.467.11","doi-asserted-by":"publisher","DOI":"10.1159\/000322497"},{"key":"2024102902000841000_94.6.467.12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"2024102902000841000_94.6.467.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"2024102902000841000_94.6.467.14","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"2024102902000841000_94.6.467.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"2024102902000841000_94.6.467.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"2024102902000841000_94.6.467.17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316625"},{"key":"2024102902000841000_94.6.467.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010209"},{"key":"2024102902000841000_94.6.467.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b907b"},{"key":"2024102902000841000_94.6.467.20","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23412"},{"key":"2024102902000841000_94.6.467.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"2024102902000841000_94.6.467.22","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"2024102902000841000_94.6.467.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1998.tb05968.x"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:01:18Z","timestamp":1730192478000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,15]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/jnnp-2022-330519"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330519","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}